The vaccines targeting DCs in vivo do not need apheresis to gather autologous DCs for vaccine manufacturing, and instead, specific antigens targeting receptors on DCs in vivo are injected into the body, such as the vaccine CDX-1401 targeting DEC205+cDC1s in multiple tumors including ovarian cancer, which contains the DEC205 antibody fused with NY-ESO-1 and a TLR agonist (47). Here, LY75 is linked to ovarian carcinoma.